Abstract

To describe perioperative outcomes following robot-assisted prostatectomy performed by a single surgeon during transitions between da Vinci standard/Si/Xi and the single port. Perioperative data were retrospectively evaluated of the first 40 consecutive robot-assisted radical prostatectomies performed by a single surgeon using the da Vinci standard, Si, Xi and single port. A total of 160 patients were included. We matched standard vs Si (Match 1), Si vs Xi (Match 2) and Xi vs single port (Match 3) cohort. Mann–Whitney and Fisher’s tests were used to test the difference among the groups. Univariate and multivariate logistic regression analyses were adopted to evaluate the predictors of overall and major complications. Single-port procedures in Match 3 showed significant shorter median operative time than Xi. Both Si and single-port groups showed significantly less median blood loss, a shorter median length of stay, respectively, than standard group in Match 1 and than Xi group in Match 3. 1 standard group patient required conversion to open surgery for an unsolvable conflict of the robotic arms. No other intraoperative complications were noted. On univariate and multivariate analyses, the da Vinci platform model was not a predicting factor of major complications (Clavien–Dindo ≥ 3). We described how technological progress impacted peri and postoperative outcomes during transitions between robotic surgical platforms for radical prostatectomy. In particular, the technological improvements associated to the increased surgeon’s expertise made the transition to the single port safe and effective when compared with previous platforms.

Highlights

  • Since its initial approval in 2000 by the United States Food and Drug Administration (FDA), the da Vinci surgical robot

  • The aim of this study was to describe the approach to each new platform comparing the outcomes among the first 40 RobotAssisted Radical Prostatectomy (RARP) performed by a single surgeon using da Vinci S, Si, Xi & SP platform, evaluating if the transition to novel robotic technology was associated with adverse patient outcomes

  • The da Vinci Si cohort consisted of the first 40 consecutive RARP performed between May 2014 and October 2015 at the University of Illinois at Chicago (UIC)

Read more

Summary

Introduction

Since its initial approval in 2000 by the United States Food and Drug Administration (FDA), the da Vinci surgical robot Between 2003 and 2013, the proportion of RobotAssisted Radical Prostatectomy (RARP) rose from 1.8 to 85%[2] and since the release of the initial da Vinci standard (S) model, there have been several iterations of this platform released including the Si (2009), Xi (2014) and single-port (SP) (2018) systems. Transitions in surgical technology represent both a possible technological improvement as well as the potential to impact patient safety. While marketing for these technologies often focus on novel functionalities or features, if surgeons are unfamiliar or inexperienced with these systems, there is a potential for adverse patient outcomes.

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call